- CA$11.35m
- CA$67.51m
- CA$53.91m
- 30
- 69
- 16
- 33
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.21 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -33.58% |
Financial Summary
Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | 6.58 | 7.47 | 13.56 | 27.75 | 53.91 | 62.55 | 75.83 | 65.2% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Directors
- Richard MacKay CHM (86)
- Frederic Fasano PRE (53)
- Steven Saviuk CEO (62)
- Luc Mainville CFO (57)
- Marc Leger SVP
- Helen Saviuk VOP
- Guy Allard VPR
- Nathalie Therrien VPR
- Jeff Skinner VBD
- Maureen Brennan IND (66)
- Vincent Hogue IND (58)
- Michel Trudeau IND (59)
- Michael Wells IND (53)
- Last Annual
- October 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- March 27th, 2003
- Public Since
- February 20th, 2019
- No. of Employees
- 100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 98,675,427
- Address
- 16667 Hymus Blvd, KIRKLAND, H9H 4R9
- Web
- https://valeopharma.com/
- Phone
- +1 5146938832
- Contact
- Frederic Dumais
- Auditors
- PricewaterhouseCoopers LLC
Upcoming Events for VPH
Q3 2024 Valeo Pharma Inc Earnings Release
Similar to VPH
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
Charlotte's Web Holdings
Toronto Stock Exchange
FAQ
As of Today at 19:22 UTC, shares in Valeo Pharma are trading at CA$0.12. This share price information is delayed by 15 minutes.
Shares in Valeo Pharma last closed at CA$0.12 and the price had moved by -76.77% over the past 365 days. In terms of relative price strength the Valeo Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -78.09% over the past year.
The overall consensus recommendation for Valeo Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Valeo Pharma does not currently pay a dividend.
Valeo Pharma does not currently pay a dividend.
Valeo Pharma does not currently pay a dividend.
To buy shares in Valeo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.12, shares in Valeo Pharma had a market capitalisation of CA$11.35m.
Here are the trading details for Valeo Pharma:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: VPH
Based on an overall assessment of its quality, value and momentum Valeo Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Valeo Pharma is CA$0.50. That is 334.78% above the last closing price of CA$0.12.
Analysts covering Valeo Pharma currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.20 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Valeo Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -31.67%.
As of the last closing price of CA$0.12, shares in Valeo Pharma were trading -48.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Valeo Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Valeo Pharma's management team is headed by:
- Richard MacKay - CHM
- Frederic Fasano - PRE
- Steven Saviuk - CEO
- Luc Mainville - CFO
- Marc Leger - SVP
- Helen Saviuk - VOP
- Guy Allard - VPR
- Nathalie Therrien - VPR
- Jeff Skinner - VBD
- Maureen Brennan - IND
- Vincent Hogue - IND
- Michel Trudeau - IND
- Michael Wells - IND